Sanofi has increased its corporate venture capital arm, Sanofi Ventures, by $625 million, bolstering its capacity to invest in early- and late-stage biotechnology and digital health companies. This cash infusion brings the fund’s total capital to $1.4 billion, positioning the firm to lead or co-lead rounds at a time when independent venture capital is cautious. Sanofi Ventures has backed several promising drug developers, aiming to accelerate innovation pipelines through strategic investments.